首页 > 最新文献

Journal of Cancer Policy最新文献

英文 中文
Capturing breast cancer subtypes in cancer registries: insights into real-world incidence and survival.
IF 2 Q3 HEALTH POLICY & SERVICES
Journal of Cancer Policy
Pub Date : 2025-03-03 DOI: 10.1016/j.jcpo.2025.100567
Larissa Vaz-Gonçalves, Louise Marquart-Wilson, Melinda M Protani, Meghan T Stephensen, Julie Moore, Michelle F Morris, Jodi M Saunus, Marina M Reeves

Background: Breast cancer treatment is guided by diagnostic subtyping, yet cancer registries do not routinely capture this information, and real-world studies reporting subtype-specific incidence and survival do not reflect contemporary clinical management.

Methods: We analysed breast cancer incidence and survival using Queensland cancer registry data (2017-2019), stratifying by hormone receptor (HR) and HER2 status.

Results: Subtype-specific, age-standardised incidence rates were: 125.6 HR+/HER2- cases/100,000 women (76.0% of all diagnoses), followed by 17.7/100,000 for triple-negative (TNBC; 10.3%), 15.0/100,000 for HR+/HER2+ (8.7%), and 8.6/100,000 for HR-/HER2+ (5.0%). Compared to HR+/HER2-, all other subtypes had poorer breast cancer-specific survival (BCSS) and overall survival (OS; except HR+/HER2+ for OS) at 2-years, with OS associations attenuated but still significant for TNBC at 4-years. Stratifying by stage at diagnosis, TNBC had consistently poorer 2-year BCSS in those with stage I-III TNBC (HRadj>7), and marginally poorer in those with stage IV.

Conclusions: HR+/HER2- breast cancer is the most common subtype and has the best short-term prognosis. TNBC has markedly poorer short-term survival, even when diagnosed at an early stage. This study provides real-world data for benchmarking breast cancer incidence and survival, and highlights the importance of capturing receptor status and stage for cancer surveillance.

Policy summary: Routinely capturing breast cancer subtypes and stages in cancer registries needs to be prioritised to assess the real-world efficacy of evolving targeted therapies and to inform tailored surveillance for high-risk subtypes.

{"title":"Capturing breast cancer subtypes in cancer registries: insights into real-world incidence and survival.","authors":"Larissa Vaz-Gonçalves, Louise Marquart-Wilson, Melinda M Protani, Meghan T Stephensen, Julie Moore, Michelle F Morris, Jodi M Saunus, Marina M Reeves","doi":"10.1016/j.jcpo.2025.100567","DOIUrl":"https://doi.org/10.1016/j.jcpo.2025.100567","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer treatment is guided by diagnostic subtyping, yet cancer registries do not routinely capture this information, and real-world studies reporting subtype-specific incidence and survival do not reflect contemporary clinical management.</p><p><strong>Methods: </strong>We analysed breast cancer incidence and survival using Queensland cancer registry data (2017-2019), stratifying by hormone receptor (HR) and HER2 status.</p><p><strong>Results: </strong>Subtype-specific, age-standardised incidence rates were: 125.6 HR+/HER2- cases/100,000 women (76.0% of all diagnoses), followed by 17.7/100,000 for triple-negative (TNBC; 10.3%), 15.0/100,000 for HR+/HER2+ (8.7%), and 8.6/100,000 for HR-/HER2+ (5.0%). Compared to HR+/HER2-, all other subtypes had poorer breast cancer-specific survival (BCSS) and overall survival (OS; except HR+/HER2+ for OS) at 2-years, with OS associations attenuated but still significant for TNBC at 4-years. Stratifying by stage at diagnosis, TNBC had consistently poorer 2-year BCSS in those with stage I-III TNBC (HR<sub>adj</sub>>7), and marginally poorer in those with stage IV.</p><p><strong>Conclusions: </strong>HR+/HER2- breast cancer is the most common subtype and has the best short-term prognosis. TNBC has markedly poorer short-term survival, even when diagnosed at an early stage. This study provides real-world data for benchmarking breast cancer incidence and survival, and highlights the importance of capturing receptor status and stage for cancer surveillance.</p><p><strong>Policy summary: </strong>Routinely capturing breast cancer subtypes and stages in cancer registries needs to be prioritised to assess the real-world efficacy of evolving targeted therapies and to inform tailored surveillance for high-risk subtypes.</p>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":" ","pages":"100567"},"PeriodicalIF":2.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Delivering quality cancer care in rural and coastal settings: Experiences of a large-scale integrated cancer transformation programme
IF 2 Q3 HEALTH POLICY & SERVICES
Journal of Cancer Policy
Pub Date : 2025-03-01 DOI: 10.1016/j.jcpo.2024.100544
David Nelson , Kathie McPeake , Samuel Cooke , Ros Kane , Peter Selby
Short introduction text: This abstract reports on the success of the system-wide, integrated Macmillan Living with Cancer Programme in the predominantly rural and coastal setting of Lincolnshire, England.
{"title":"Delivering quality cancer care in rural and coastal settings: Experiences of a large-scale integrated cancer transformation programme","authors":"David Nelson ,&nbsp;Kathie McPeake ,&nbsp;Samuel Cooke ,&nbsp;Ros Kane ,&nbsp;Peter Selby","doi":"10.1016/j.jcpo.2024.100544","DOIUrl":"10.1016/j.jcpo.2024.100544","url":null,"abstract":"<div><div><strong>Short introduction text:</strong> This abstract reports on the success of the system-wide, integrated Macmillan Living with Cancer Programme in the predominantly rural and coastal setting of Lincolnshire, England.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100544"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143562241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A scoping review of the association of ethnicity and cancer care pathways within Europe
IF 2 Q3 HEALTH POLICY & SERVICES
Journal of Cancer Policy
Pub Date : 2025-03-01 DOI: 10.1016/j.jcpo.2024.100546
Beth Russell , Ailbhe Lawlor , Lottie Phillips , Sophie Pilleron , Katrien Vanthomme , Mieke Van Hemelrijck , Ajay Aggarwal
{"title":"A scoping review of the association of ethnicity and cancer care pathways within Europe","authors":"Beth Russell ,&nbsp;Ailbhe Lawlor ,&nbsp;Lottie Phillips ,&nbsp;Sophie Pilleron ,&nbsp;Katrien Vanthomme ,&nbsp;Mieke Van Hemelrijck ,&nbsp;Ajay Aggarwal","doi":"10.1016/j.jcpo.2024.100546","DOIUrl":"10.1016/j.jcpo.2024.100546","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100546"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Social inequalities in the return to work after lower gastrointestinal cancer following medical rehabilitation
IF 2 Q3 HEALTH POLICY & SERVICES
Journal of Cancer Policy
Pub Date : 2025-03-01 DOI: 10.1016/j.jcpo.2024.100542
Johannes Soff , Ibrahim Demirer , Clara Breidenbach , Nicole Ernstmann , Paula Heidkamp , Lina Heier , Kati Hiltrop , Sophie Schellack , Christoph Kowalski
{"title":"Social inequalities in the return to work after lower gastrointestinal cancer following medical rehabilitation","authors":"Johannes Soff ,&nbsp;Ibrahim Demirer ,&nbsp;Clara Breidenbach ,&nbsp;Nicole Ernstmann ,&nbsp;Paula Heidkamp ,&nbsp;Lina Heier ,&nbsp;Kati Hiltrop ,&nbsp;Sophie Schellack ,&nbsp;Christoph Kowalski","doi":"10.1016/j.jcpo.2024.100542","DOIUrl":"10.1016/j.jcpo.2024.100542","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100542"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing early detection of ovarian cancer: A retrospective analysis using C the signs clinical decision support system
IF 2 Q3 HEALTH POLICY & SERVICES
Journal of Cancer Policy
Pub Date : 2025-03-01 DOI: 10.1016/j.jcpo.2024.100552
S. Dadhania , R. Edgerley , D. Milliken , B. Bakshi , M. Payling
{"title":"Enhancing early detection of ovarian cancer: A retrospective analysis using C the signs clinical decision support system","authors":"S. Dadhania ,&nbsp;R. Edgerley ,&nbsp;D. Milliken ,&nbsp;B. Bakshi ,&nbsp;M. Payling","doi":"10.1016/j.jcpo.2024.100552","DOIUrl":"10.1016/j.jcpo.2024.100552","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100552"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143562144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trials that treat what should be observed: SWOG 2308, a study of mosunetuzumab-axgb in asymptomatic low tumor burden follicular lymphoma
IF 2 Q3 HEALTH POLICY & SERVICES
Journal of Cancer Policy
Pub Date : 2025-03-01 DOI: 10.1016/j.jcpo.2025.100560
Myung Sun Kim , Vinay Prasad
S2308 is a study comparing rituximab, which is not the standard of care, to.mosunetuzumab-axgb, a first-in-class CD20-directed CD3 T-cell engager with.unknown long term side effects, in a heterogeneous patient population in which a fifth.of patients do not need treatment for at least 10 years. The treatment of asymptomatic.low tumor burden follicular lymphoma is watchful waiting and no treatment has.demonstrated improvement in OS after long term follow up. Beyond the limitations of.the study design, this study would be the basis of regulatory approval and cooperative.groups receiving federal funding should not be running this trial. Study sites are US based and mostly include community oncology practices, risking inclusion of very low.risk patients that are most likely to be harmed by any treatment
{"title":"Trials that treat what should be observed: SWOG 2308, a study of mosunetuzumab-axgb in asymptomatic low tumor burden follicular lymphoma","authors":"Myung Sun Kim ,&nbsp;Vinay Prasad","doi":"10.1016/j.jcpo.2025.100560","DOIUrl":"10.1016/j.jcpo.2025.100560","url":null,"abstract":"<div><div>S2308 is a study comparing rituximab, which is not the standard of care, to.mosunetuzumab-axgb, a first-in-class CD20-directed CD3 T-cell engager with.unknown long term side effects, in a heterogeneous patient population in which a fifth.of patients do not need treatment for at least 10 years. The treatment of asymptomatic.low tumor burden follicular lymphoma is watchful waiting and no treatment has.demonstrated improvement in OS after long term follow up. Beyond the limitations of.the study design, this study would be the basis of regulatory approval and cooperative.groups receiving federal funding should not be running this trial. Study sites are US based and mostly include community oncology practices, risking inclusion of very low.risk patients that are most likely to be harmed by any treatment</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100560"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bridging the gap: Enablers and barriers in implementing global cancer care efficiency metrics - A qualitative implementation study
IF 2 Q3 HEALTH POLICY & SERVICES
Journal of Cancer Policy
Pub Date : 2025-03-01 DOI: 10.1016/j.jcpo.2024.100543
Ana Sofia V. Carvalho , Óscar Brito Fernandes , Damir Ivanković , Erica Barbazza , Mădălina Iamandei , Eduardo Pisani , Niek Klazinga , Dionne Kringos

Key category

Health Systems & Quality Cancer Care∼
{"title":"Bridging the gap: Enablers and barriers in implementing global cancer care efficiency metrics - A qualitative implementation study","authors":"Ana Sofia V. Carvalho ,&nbsp;Óscar Brito Fernandes ,&nbsp;Damir Ivanković ,&nbsp;Erica Barbazza ,&nbsp;Mădălina Iamandei ,&nbsp;Eduardo Pisani ,&nbsp;Niek Klazinga ,&nbsp;Dionne Kringos","doi":"10.1016/j.jcpo.2024.100543","DOIUrl":"10.1016/j.jcpo.2024.100543","url":null,"abstract":"<div><h3>Key category</h3><div>Health Systems &amp; Quality Cancer Care∼</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100543"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PRE-ACT: Prediction of Radiotherapy side Effects using explainable AI for patient Communication and Treatment modification
IF 2 Q3 HEALTH POLICY & SERVICES
Journal of Cancer Policy
Pub Date : 2025-03-01 DOI: 10.1016/j.jcpo.2024.100537
Yuqin Liang , Paolo Bajardi , Guido Bologna , Francesco Bonchi , Gabriella Cortellessa , Andre Dekker , Francesca Fracasso , Manuela Joore , Nikos Paragios , Tim Rattay , Sofia Rivera , Cheryl Roumen , Johan van Soest , Alberto Traverso , Karolien Verhoeven , Iordanis Koutsopoulos , Christopher J. Talbot , PRE-ACT study consortium
PRE-ACT leverages Artificial Intelligence (AI) to predict radiotherapy side effects in breast cancer patients, integrating complex imaging and genomics data. This Horizon Europe project aims to enhance shared decision-making by providing explainable predictions and tailored interventions, advancing personalised radiotherapy and improving patient outcomes.
{"title":"PRE-ACT: Prediction of Radiotherapy side Effects using explainable AI for patient Communication and Treatment modification","authors":"Yuqin Liang ,&nbsp;Paolo Bajardi ,&nbsp;Guido Bologna ,&nbsp;Francesco Bonchi ,&nbsp;Gabriella Cortellessa ,&nbsp;Andre Dekker ,&nbsp;Francesca Fracasso ,&nbsp;Manuela Joore ,&nbsp;Nikos Paragios ,&nbsp;Tim Rattay ,&nbsp;Sofia Rivera ,&nbsp;Cheryl Roumen ,&nbsp;Johan van Soest ,&nbsp;Alberto Traverso ,&nbsp;Karolien Verhoeven ,&nbsp;Iordanis Koutsopoulos ,&nbsp;Christopher J. Talbot ,&nbsp;PRE-ACT study consortium","doi":"10.1016/j.jcpo.2024.100537","DOIUrl":"10.1016/j.jcpo.2024.100537","url":null,"abstract":"<div><div>PRE-ACT leverages Artificial Intelligence (AI) to predict radiotherapy side effects in breast cancer patients, integrating complex imaging and genomics data. This Horizon Europe project aims to enhance shared decision-making by providing explainable predictions and tailored interventions, advancing personalised radiotherapy and improving patient outcomes.</div></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100537"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Establishing standards for integrated cancer care for people experiencing homelessness: A delphi study
IF 2 Q3 HEALTH POLICY & SERVICES
Journal of Cancer Policy
Pub Date : 2025-03-01 DOI: 10.1016/j.jcpo.2024.100547
Alejandro Gil-Salmeron , Igor Grabovac
{"title":"Establishing standards for integrated cancer care for people experiencing homelessness: A delphi study","authors":"Alejandro Gil-Salmeron ,&nbsp;Igor Grabovac","doi":"10.1016/j.jcpo.2024.100547","DOIUrl":"10.1016/j.jcpo.2024.100547","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100547"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PRiSM: Specialist palliative Care's role in cancer survivorship model developing European consensus recommendations on the role of specialist palliative care in cancer survivorship to inform a model of care
IF 2 Q3 HEALTH POLICY & SERVICES
Journal of Cancer Policy
Pub Date : 2025-03-01 DOI: 10.1016/j.jcpo.2024.100541
Amy Taylor , Andrew Davies
{"title":"PRiSM: Specialist palliative Care's role in cancer survivorship model developing European consensus recommendations on the role of specialist palliative care in cancer survivorship to inform a model of care","authors":"Amy Taylor ,&nbsp;Andrew Davies","doi":"10.1016/j.jcpo.2024.100541","DOIUrl":"10.1016/j.jcpo.2024.100541","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"43 ","pages":"Article 100541"},"PeriodicalIF":2.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143563460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Journal of Cancer Policy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1